Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

More importantly, if Hims can make a comeback during the playoffs, it will inject fresh energy into the Bucks' roster and could be key to turning the tide in crucial games. Discussing Hims's role ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading, in an echo of ...

Hims & Hers Health shares plunged 18% in extended ... in part because of the success of its popular new weight loss offering. The company said its GLP-1 offering generated more than $225 million ...

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

The problem is we have a lot of treatments that we can have success with in our country, [but] we don’t have a lot of ways right now with the branded drugs to have access,” Hims & Hers ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized ...